Fluorescent-Conjugated ZnO Nanostructures Exhibited 3D Anti-Tumor Efficacy Against Drug-Resistant Cancers Through Cholesterol-Mediated ROS Regulation
Antioxidants · 28.07.2026 · 15 (8) · 935
DOI: 10.3390/antiox15080935 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 28.07.2026. Verfasst von Salida Ali und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong 999077, Chin…. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen-Hong Kong-Macau Science and Technology Program, Seed Fund for PI Research-Translational and Applied Research, National Natural Science Foundation of China.
Abstract (Originalsprache)
ZnO nanoparticles (ZnO NPs) have been widely investigated in the biomedical field, particularly their anti-tumor efficacy. The potential of ZnO hierarchical structures (ZnO HSs) in tumor cell eradication remains largely unexplored in prostate cancer (PCa) and thyroid cancer (TC). In this study, we successfully synthesized and characterized ZnO NPs and ZnO HSs using green tea extract (Camellia sinensis) as a reducing agent and conjugation of FIT-C tracking for both ZnO NPs and ZnO HSs. UV-vis spectrophotometry, Dynamic Light Scattering (DLS), FTIR, XDR, SEM and TEM revealed significant differences in morphology between ZnO NPs and ZnO HSs. Our in vitro experiments demonstrated that SNPs were more effective on aggressive PCa and TC cell lines compared to ZnO NPs. Notably, ZnO HSs exhibited enhanced cytotoxicity in 3D tumor cell spheroid models. Mechanistically, ZnO HSs induced apoptosis through cholesterol-mediated reactive oxygen species (ROS) generation. Our in vivo study revealed no histopathological changes in major organs (liver, kidneys, spleen and lungs), emphasizing the safe administration of both ZnO NPs and ZnO HSs. Our study synthesized FITC-conjugated non-spherical ZnO nanoparticles, providing evidence for a novel treatment strategy for hormone-related cancers and prospective fluorescent-guided nanomedicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Urology, Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong 999077, China.
- Department of Otolaryngology-Head and Neck Surgery, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen 518033, China.
- Nuclear Technology Research and Development Center, Thailand Institute of Nuclear Technology (Public Organization), Nakhon Nayok 26120, Thailand.
- Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
ORCID-Profile: Yu Li, Yongle Zhan, Rong Na
Förderung
- Shenzhen-Hong Kong-Macau Science and Technology Program
- Seed Fund for PI Research-Translational and Applied Research
- National Natural Science Foundation of China
- The project for the construction of key disciplines in Futian District
- project for the construction of key disciplines in Futian District
Zitieren
APA
Ali, S., Li, Y., Yotnarong, O., Shi, R., Ma, R., Yao, C., Ruan, X., Huang, J., Huang, D., Zhan, Y., Tangthong, T., & Na, R. (2026). Fluorescent-Conjugated ZnO Nanostructures Exhibited 3D Anti-Tumor Efficacy Against Drug-Resistant Cancers Through Cholesterol-Mediated ROS Regulation. Antioxidants, 15(8), 935. https://doi.org/10.3390/antiox15080935
Vancouver
Ali S, Li Y, Yotnarong O, Shi R, Ma R, Yao C, et al. Fluorescent-Conjugated ZnO Nanostructures Exhibited 3D Anti-Tumor Efficacy Against Drug-Resistant Cancers Through Cholesterol-Mediated ROS Regulation. Antioxidants. 2026;15(8):935. doi:10.3390/antiox15080935
BibTeX
@article{Ali2026,
author = {Ali, Salida and Li, Yu and Yotnarong, Ontana and Shi, Ruofan and Ma, Ruochen and Yao, Chi and Ruan, Xiaohao and Huang, Jingyi and Huang, Da and Zhan, Yongle and Tangthong, Theeranan and Na, Rong},
title = {Fluorescent-Conjugated ZnO Nanostructures Exhibited 3D Anti-Tumor Efficacy Against Drug-Resistant Cancers Through Cholesterol-Mediated ROS Regulation},
journal = {Antioxidants},
year = {2026},
volume = {15},
number = {8},
pages = {935},
doi = {10.3390/antiox15080935}
}
EUVIMED